# Solid Biosciences Inc. (SLDB) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Pharmaceuticals. Price $10.25, market value $1.1 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Solid Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / sales: 135.8×**. Each dollar of revenue is priced at 135.8×, a level that requires very high margins or very fast growth to justify.
- **Price / book: 2.9×**. The shares trade at 2.9× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -17.1%** (5-yr avg -87.0%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -96.8%**. Return on equity is negative because earnings are negative.
- **Return on assets: -37.0%**. Each dollar of assets produces -37.0% of profit.

## Growth
- **EPS growth (1 yr): 35.0%**. Earnings per share rose 35.0%.

## Financial health
- **Current ratio: 6.14** (quick 6.14). Current assets cover the next year's liabilities 6.14 times.
- **Piotroski F-score: 2/9**. 2 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Solid Biosciences Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (12 analysts). 12 analysts cover Solid Biosciences Inc.; the consensus is strong_buy, with an average price target of $18.67 (+82% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 84.4%** (YTD 81.7%, 3-mo 53.0%). The shares are up 84.4% over twelve months including dividends.
- **From 52-week high: -10.5%** (170.4% above the low). Trading 10% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 61**. An RSI of 61 is neutral.
- **Beta (1 yr): 2.16** (volatility 80%). Beta of 2.16 against the S&P 500: the shares move much more than the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=SLDB · Page: https://foliofundamentals.com/stocks/sldb

Not investment advice.